BioSpace News Archive

Proteostasis Therapeutics, Inc., announced that Marija Zecevic, Ph.D., the Company’s Chief Commercial Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:00 p.m. ET at the Lotte New York Palace.

CVS Health Corporation announced operating results for the three months and year ended December 31, 2018.

Marker Therapeutics, Inc. (Nasdaq:MRKR), today announced that its President and Chief Executive Officer, Peter L. Hoang, and Chief Development Officer, Dr. Juan F. Vera, will be presenting at the CAR-TCR Summit Europe, which is being held in London, UK from February 25-27.

CTI BioPharma Corp. announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel.

Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City.

On Wednesday, February 27, 2019, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, and Chief Operating Officer, Rhonda Robb, will present at the 8th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. Eastern Time.

Applications of the treatment will expand to different indications in need to regenerative therapeutic strategies, including scar removal, burns, and pressure/diabetic foot ulcers

Continued focus on the patient recruitment for the CONDUCT study

Austrian GENSPEED Biotech GmbH and Virogates A/S have commenced a partnership to develop a rapid test for the risk classification of acute and chronic patients on site.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, announced the completion of full enrollment in the ORCA-1 trial of cytisinicline.